3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Phase 2
1
Status
Completed
4
Unknown
3
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Uveal Melanoma
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Opioid-Related Disorders
1
Myocardial Reperfusion Injury
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Choroid Diseases
1
Cardiotoxicity
1
Interventions
Cisplatin
509
Cyclophosphamide
360
Carboplatin
352
Radiotherapy
350
Capecitabine
329
Paclitaxel
325
Oxaliplatin
324
Gemcitabine
319
Docetaxel
311
Fluorouracil
283
Drug Therapy
243
apatinib
242
Bevacizumab
229
camrelizumab
214
Etoposide
200
Irinotecan
176
Doxorubicin
175
Leucovorin
161
Dexamethasone
160
sintilimab
142
pembrolizumab
138
anlotinib
136
Pemetrexed
136
Cytarabine
136
toripalimab
129
Neoadjuvant Therapy
122
S 1 (combination)
120
Vincristine
119
Rituximab
117
Radiosurgery
117
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Interventional
×
salicylhydroxamic acid
×
Clear all
NCT04850664
2021-08-06
CBOT-OUD
Evon Medics LLC
Phase 2
Unknown
190 enrolled
NCT02471885
2020-04-15
ERIC-ONC
University College, London
Phase NA
Unknown
128 enrolled
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled